½ÃÀ庸°í¼­
»óǰÄÚµå
1733809

Áø´Ü¿ë AI ½ÃÀå ±Ô¸ð : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÀûÀÀ Áúȯº°, Áö¿ª ¹üÀ§º° ¹× ¿¹Ãø

Artificial Intelligence In Diagnostics Market Size By Product, By Type, By Application, By Disease Indication, By Geographic Scope And Forecast

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Verified Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 202 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áø´Ü¿ë AI ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

Áø´Ü¿ë AI ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 12¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2026³âºÎÅÍ 2032³â¿¡ °ÉÃÄ 33.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇϸç, 2032³â¿¡´Â 106¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áø´Ü¿ë AIÀº º¹ÀâÇÑ ¾Ë°í¸®Áò°ú ¸Ó½Å·¯´× ±â¼úÀ» »ç¿ëÇÏ¿© »çÁø, ȯÀÚÀÇ º´·Â, °Ë»ç ¼Ò°ß µîÀÇ ÀÇ·á µ¥ÀÌÅ͸¦ Æò°¡Çϰí ÀÇ·á Àü¹®°¡°¡ º¸´Ù Á¤È®Çϰí È¿À²ÀûÀ¸·Î Áúº´À» Áø´ÜÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÔ´Ï´Ù.

Áø´Ü¿ë AIÀÇ ÀÀ¿ë¿¡´Â ÀÇ·á È­»óÀÇ ÇØ¼®ÀÇ °³¼±, Àǽɽº·¯¿î ÁúȯÀ» ƯÁ¤Çϱâ À§ÇÑ AI¸¦ Ȱ¿ëÇÑ Áõ»ó °Ë»ç±âÀÇ ÀÛ¼º, ¹éÇ÷º´ µîÀÇ ÁúȯÀÇ Ç÷¾× »ùÇà ó¸®ÀÇ ÀÚµ¿È­ µîÀÌ ÀÖ½À´Ï´Ù.

Áø´Ü¿ë AI ½ÃÀåÀº CAGR 33.7%·Î ¼ºÀåÇϸç, 2032³â ¸»±îÁö 106¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Áø´Ü¿ë AI ¼¼°è ½ÃÀå ¿ªÇÐ

Áø´Ü¿ë AI ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ½ÃÀå ¿ªÇÐÀº ´ÙÀ½°ú °°½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡ : ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶óº¸´Ù È¿À²ÀûÀ̰í Á¤È®ÇÑ Áø´Ü ¹æ¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù. AI´Â À̰ÍÀ» Á¦°øÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¸¸¼º ÁúȯÀº Àü ¼¼°è »ç¸ÁÀÚÀÇ 71%¸¦ Â÷ÁöÇÕ´Ï´Ù. ƯÈ÷ ½ÉÇ÷°ü ÁúȯÀº ¸¸¼º Áúȯ¿¡ ÀÇÇÑ »ç¸ÁÀÇ ´ëºÎºÐ(¿¬°£ 1,790¸¸¸í)À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÇコÄɾ¼­ AI äÅà Ȯ´ë : ÀÇ·á Á¦°øÀÚ´Â Áø´Ü Á¤È®µµ¿Í È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â AIÀÇ ÀáÀç·ÂÀ» ºü¸£°Ô ÀνÄÇϰí ÀÖ½À´Ï´Ù. MIT Technology Review Insights°¡ ½Ç½ÃÇÑ Á¶»ç¿¡ µû¸£¸é °Ç°­ °ü¸® ¸®´õÀÇ 78%´Â AI/ML(¸Ó½Å·¯´×)ÀÇ ³ë·ÂÀÌ ¹æ»ç¼±ÇÐ, ½ÉÀ庴ÇÐ, º´¸®ÇÐ µîÀÇ ºÐ¾ß¿¡¼­ ÀÌ¹Ì °¡Ä¡¸¦ ³ôÀ̰í ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù.

°Ç°­ °ü¸® ºñ¿ë »ó½Â°ú ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀÇ Çʿ伺 : Áø´Ü¿ë AI´Â È¿À²¼º°ú Á¤È®¼ºÀ» Çâ»ó½ÃÄÑ °Ç°­ °ü¸® ºñ¿ëÀ» ÁÙÀÌ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. ¸ÞµðÄÉ¾î ¸ÞµðÄÉÀÌµå ¼­ºñ½º ¼¾ÅÍ(CMS)´Â 2019³âºÎÅÍ 2028³â±îÁö ¹Ì±¹ÀÇ °Ç°­ °ü¸® ÁöÃâÀÌ ¿¬Æò±Õ 5.4% Áõ°¡ÇßÀ¸¸ç, 2028³â¿¡´Â 6Á¶ 2,000¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ Áø´ÜÀº ÀÌ·¯ÇÑ ±ÞµîÇÏ´Â ÁöÃâÀÇ »è°¨À» Áö¿øÇÕ´Ï´Ù.

ÁÖ¿ä °úÁ¦

³ôÀº µµÀÔ ºñ¿ë : µµÀÔ ºñ¿ëÀÌ ³ôÀº °ÍÀº Áø´Ü¿ë AI µµÀÔÀÇ ÁÖ¿ä À庮ÀÔ´Ï´Ù. AI ±â¼úÀ» ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ ÅëÇÕÇÏ·Á¸é Çϵå¿þ¾î, ¼ÒÇÁÆ®¿þ¾î ¹× ±³À°¿¡ »ó´çÇÑ ÀÚ±ÝÀ» ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ¸¹Àº ÀÇ·á½Ã¼³, ƯÈ÷ ¼Ò±Ô¸ð ½Ã¼³¿¡¼­´Â ÀÌ·¯ÇÑ Ãʱâ ÁöÃâÀ» Á¶´ÞÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖÀ¸¸ç, º¸±ÞÀ» ¹æÇØÇÏ°í ½ÃÀå ¼ºÀå °¡´É¼ºÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.

µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾È¿¡ ´ëÇÑ ¿ì·Á : µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾È¿¡ ´ëÇÑ ¿ì·Á´Â AI Áø´Ü ½ÃÀå¿¡ Å« µµÀüÀÔ´Ï´Ù. AI ½Ã½ºÅÛÀÇ »ç¿ëÀº ±â¹Ð¼ºÀÌ ³ôÀº ȯÀÚ µ¥ÀÌÅÍÀÇ ¼öÁý°ú ºÐ¼®À» ÇÊ¿ä·Î ÇÏ¸ç ¹Ì±¹ÀÇ HIPAA¿Í À¯·´ÀÇ GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)°ú °°Àº µ¥ÀÌÅÍ º¸È£ ±ÔÁ¤ Áؼö¿¡ °üÇÑ ¹®Á¦¸¦ Á¦±âÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ °Ç°­ Á¤º¸ÀÇ À¯Ãâ°ú ¿À¿ëÀº ¹ýÀû °á°ú¸¦ ÃÊ·¡ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚ¿Í °Ç°­ °ü¸® Á¦°ø¾÷üÀÇ ½Å·Ú °ü°è¸¦ ¼Õ»ó½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ¿ì·Á´Â ÀÌÇØ°ü°èÀÚ°¡ ȯÀÚ µ¥ÀÌÅÍ º¸È£¸¦ ¼±È£Çϱ⠶§¹®¿¡ Áø´Ü¿ë AI ±â¼úÀÇ Ã¤ÅÃÀ» ´ÊÃß°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä µ¿Çâ :

AI¸¦ žÀçÇÑ À̹ÌÁö ¼Ö·ç¼ÇÀÇ Ã¤¿ë Áõ°¡ : Áø´Ü¿ë AI ½ÃÀå¿¡¼­´Â ƯÈ÷ ¹æ»ç¼±Çаú º´¸®Çп¡ À־, AI¸¦ žÀçÇÑ È­»ó ó¸® ½Ã½ºÅÛÀÇ ÀÌ¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áúº´ÀÇ Á¶±â ¹ß°ßÀÇ Á߿伺 : AI´Â ÀÇ·á ¿µ»ó, °Ë»ç °á°ú, ÀüÀÚ ÀÇ·á ±â·Ï µî ȯÀÚ µ¥ÀÌÅÍ¿¡¼­ ÆÐÅÏÀ» ã¾Æ, Á¶±â Áúº´ ½Äº°À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ¸ðµ¨Àº ÀáÀçÀûÀÎ °Ç°­ ¹®Á¦¸¦ Á¶±â ´Ü°è¿¡¼­ °¨ÁöÇÏ¿© º¸´Ù ½Å¼ÓÇÑ °³ÀÔ°ú ȯÀÚ °á°ú °³¼±À» °¡´ÉÇϰÔÇÕ´Ï´Ù.

Çù¾÷°ú ÆÄÆ®³Ê½Ê Áõ°¡ : Áø´Ü¿ë AI ½ÃÀåÀº °Ç°­ °ü¸® Á¦°ø¾÷ü, AI ¼Ö·ç¼Ç °ø±ÞÀÚ, ¿¬±¸ ±â°ü °£ÀÇ Çù·Â°ú ÆÄÆ®³Ê½ÊÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ¸®µë ±¸Ãà ¹× Å×½ºÆ®, ¹æ´ëÇÑ ±³À° µ¥ÀÌÅͼ¼Æ® »ý¼º, ÇコÄɾî ÀýÂ÷¿¡ AI ±â¼úÀ» ÅëÇÕÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • ½ÃÀåÀÇ Á¤ÀÇ
  • ½ÃÀå ¼¼ºÐÈ­
  • Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå °³¿ä
  • ½ÃÀå ÇÏÀ̶óÀÌÆ®

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÃÀå ±Ô¸ð¿Í ¼ºÀå °¡´É¼º
  • ½ÃÀå µ¿Çâ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • Porter's Five Forces ºÐ¼®

Á¦4Àå Áø´Ü¿ë AI ½ÃÀå : ±¸¼º ¿ä¼Òº°

  • Çϵå¿þ¾î
  • ¼ÒÇÁÆ®¿þ¾î

Á¦5Àå Áø´Ü¿ë AI ½ÃÀå : Áø´Üº°

  • Á¾¾çÇÐ
  • ¹æ»ç¼±ÇÐ
  • º´¸®ÇÐ
  • ½ÉÀ庴ÇÐ
  • ÈäºÎ ¹× Æó
  • ½Å°æÇÐ
  • ±âŸ

Á¦6Àå Áö¿ª ºÐ¼®

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • ÀϺ»
  • Àεµ
  • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • Ä¥·¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦7Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷
  • ½ÃÀå Á¡À¯À² ºÐ¼®

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Siemens Healthineers
  • Zebra Medical Vision
  • Riverain Technologies
  • Vuno, Inc.
  • Aidoc
  • Neural Analytics
  • Imagen Technologies
  • Digital Diagnostics, Inc.
  • GE Healthcare
  • AliveCor
  • Enlitic
  • InformAI

Á¦10Àå ½ÃÀå Àü¸Á°ú ±âȸ

  • ½ÅÈï±â¼ú
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ÅõÀÚ ±âȸ

Á¦11Àå ½ÃÀå Àü¸Á ºÎ·Ï

  • ¾à¾î ¸ñ·Ï
  • Ãâó¿Í Âü°í¹®Çå
SHW 25.06.09

Artificial Intelligence (AI) In Diagnostics Market Size and Forecast

Artificial Intelligence (AI) In Diagnostics Market size was valued at USD 1.26 Billion in 2024 and is projected to reach USD 10.68 Billion by 2032, growing at a CAGR of 33.7% from 2026 to 2032.

Artificial intelligence (AI) in diagnostics is the use of complex algorithms and machine learning techniques to evaluate medical data, such as photographs, patient histories, and laboratory findings, to help healthcare professionals, diagnose diseases more precisely and efficiently. AI systems process enormous amounts of data from a variety of sources, including X-rays, MRIs, and patient records, resulting in higher prediction accuracy and fewer diagnostic errors.

AI applications in diagnostics include improving the interpretation of medical imaging, creating AI-powered symptom checkers to identify suspected disorders, and automating blood sample processing for diseases such as leukemia.

Artificial Intelligence (AI) In Diagnostics Market is estimated to grow at a CAGR 33.7% & reach USD 10.68 Bn by the end of 2032

Global Artificial Intelligence (AI) In Diagnostics Market Dynamics

The key market dynamics that are shaping artificial intelligence in diagnostics market include:

Key Market Drivers

Increasing Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases needs more efficient and precise diagnostic methods, which AI supplies. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide. Cardiovascular disorders, in particular, are responsible for the majority of chronic disease mortality (17.9 million individuals per year). This drives AI applications in diagnostics market.

Growing Adoption of AI in Healthcare: Healthcare providers are rapidly realizing AI's potential to improve diagnosis accuracy and efficiency. According to a survey conducted by MIT Technology Review Insights, 78% of healthcare leaders believe that AI/ML (machine learning) initiatives are already adding value in disciplines such as radiology, cardiology, and pathology.

Rising Healthcare Costs and the Need for Cost-effective Solutions: AI in diagnostics helps lower healthcare expenses by increasing efficiency and accuracy. The Centers for Medicare & Medicaid Services (CMS) predicts that healthcare spending in the United States will increase at an average annual rate of 5.4% between 2019 and 2028, reaching $6.2 trillion by 2028. AI-powered diagnostics assist in reducing these escalating expenditures.

Key Challenges:

High Cost of Implementation: The high cost of implementation is a key barrier to the adoption of Artificial Intelligence (AI) in the diagnostics market. Integrating AI technologies into healthcare systems necessitates significant financial investments in hardware, software, and training. Many healthcare facilities, particularly smaller ones, struggle to cover these early expenditures, impeding widespread adoption and limiting the market's growth potential.

Data Privacy and Security Concerns: Data privacy and security concerns are a big challenge for the AI diagnostics market. The use of AI systems necessitates the collection and analysis of sensitive patient data, raising issues regarding compliance with data protection rules such as HIPAA in the US and GDPR in Europe. Any compromise or misuse of personal health information results in legal consequences and undermines trust between patients and healthcare providers. This feeling of concern slows down the adoption of AI technologies in diagnostics as stakeholders prioritize safeguarding patient data.

Key Trends:

Increasing Adoption of AI-Powered Imaging Solutions: The AI in diagnostics market is experiencing an increase in the use of AI-powered imaging systems, particularly in radiology and pathology. AI algorithms evaluate medical images more rapidly, detect minor anomalies, and provide quantitative data to aid clinical decision-making. This trend is motivated by the desire to reduce radiologist efforts while improving diagnostic accuracy.

Growing Emphasis on Early Disease Detection: AI enables earlier disease identification by finding patterns in patient data such as medical imaging, test results, and electronic health records. AI-powered symptom checkers and prediction models detect potential health issues at an early stage, allowing for more prompt interventions and better patient outcomes. This practice is gaining traction as healthcare systems focus on preventative care and population health management.

Increasing Collaborations and Partnerships: The AI in diagnostics market is marked by an increasing number of collaborations and partnerships among healthcare providers, AI solution providers, and research organizations. These collaborations aim to build and test AI algorithms, generate massive training datasets, and incorporate AI technology into healthcare procedures. Collaboration is essential for overcoming obstacles such as data privacy issues and regulatory barriers.

Global Artificial Intelligence (AI) In Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of artificial intelligence in diagnostics market:

North America:

According to Verified Market Research, North America is estimated to dominate in artificial intelligence in diagnostics market over the forecast period. North America, especially the United States, is the leader in healthcare spending and advanced technological utilization. The Centers for Medicare and Medicaid Services (CMS) predict that healthcare spending in the United States exceeded $4.1 trillion in 2020, or $12,530 per person. This significant expenditure creates a favorable environment for AI adoption in diagnostics.

The increased prevalence of chronic diseases in North America creates a demand for better diagnostic technologies. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 persons in the United States have at least one chronic disease, with 4 in 10 having two or more. This prevalence opens up a large market for AI-powered diagnostic solutions.

Furthermore, North America is home to many of the world's major AI and healthcare enterprises, as well as prestigious research universities. The National Institutes of Health (NIH) reports that it invested more than $1 billion in AI-related research initiatives in fiscal 2020. This concentration of talent and money drives innovation and market expansion in the region.

Asia Pacific:

The Asia Pacific is estimated to exhibit the highest growth in the market during the forecast period. The Asia Pacific region's elderly population is rapidly growing, resulting in increased demand for improved diagnostic equipment. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's elderly population (aged 65 and more) is predicted to more than double from 535 million in 2019 to around 1.3 billion by 2050. This demographic transition has created a substantial demand for AI-powered diagnostic solutions that are both efficient and accurate.

Growing healthcare investments in the region are boosting the use of modern technologies such as AI in diagnosis. The World Health Organization (WHO) estimates that health spending in the Western Pacific Region, which encompasses much of Asia, has been consistently increasing. For example, China's health expenditure as a percentage of GDP rose from 4.5% in 2000 to 5.4% in 2018, indicating a growing capacity to invest in advanced healthcare technologies.

Furthermore, the rising prevalence of chronic diseases in Asia Pacific is pushing the demand for more effective diagnostic tools. According to the World Health Organization, noncommunicable diseases (NCDs) account for 71% of all deaths worldwide, with a higher proportion occurring in low- and middle-income nations, many of which are in Asia Pacific. In Southeast Asia, NCDs are projected to cause 62% of all fatalities. This high disease burden is driving a growing demand for AI-powered diagnostic solutions that improve chronic condition identification and management.

Europe:

Europe region is estimated to exhibit substantial growth within the market during the forecast period. Europe's population is increasingly aging, necessitating the development of more effective diagnostic technologies. According to Eurostat, the proportion of adults 65 and older in the EU is expected to rise from 20.3% in 2019 to 29.4% by 2050. This demographic trend is projected to drive up demand for AI-powered diagnostic tools that better manage age-related health conditions.

Europe is making significant investments in AI research and development, particularly in healthcare. The European Commission has pledged to expand yearly AI investments to €20 billion starting in 2020. According to a European Parliament estimate, artificial intelligence might contribute up to €13.3 trillion to the global economy by 2030, with Europe accounting for approximately €2.7 trillion of that amount.

Furthermore, the European Union has taken proactive steps to create a favorable regulatory environment for artificial intelligence in healthcare. The European Medicines Agency (EMA) has formed a dedicated AI task group to investigate the application of AI in medication development and regulation. According to an EMA survey, 63% of respondents anticipate that artificial intelligence will have a substantial impact on medical research and regulation within the next 2-5 years.

Global Artificial Intelligence (AI) In Diagnostics Market: Segmentation Analysis

The Artificial Intelligence (AI) In Diagnostics Market is segmented based on Component, Diagnosis, and Geography.

Artificial Intelligence (AI) In Diagnostics Market, By Component

  • Hardware
  • Software
  • Services

Based on Component, the market is segmented into Hardware, Services, and Software. The software segment is estimated to dominate the artificial intelligence in diagnostics market due to an increase in demand for AI-enabled diagnostic products that improve illness detection accuracy and efficiency. The software's ability to interface with existing healthcare systems and improve diagnostic workflows is fueling fast expansion. As healthcare providers face increasing patient volumes and a shortage of professionals, their reliance on modern software solutions is projected to grow considerably.

Artificial Intelligence (AI) In Diagnostics Market, By Diagnosis

  • Cardiology
  • Oncology
  • Pathology
  • Radiology
  • Chest and Lung
  • Neurology
  • Others

Based on Diagnosis, the market is segmented into Cardiology, Oncology, Pathology, Radiology, Chest & Lung, Neurology, and Others. The neurology segment is estimated to dominate the artificial intelligence in the diagnostics market due to the rising occurrence of neurological illnesses such as Alzheimer's and Parkinson's disease, which require precise and early diagnoses. As the population ages, the demand for sophisticated diagnostic tools in neurology is predicted to increase, cementing the market's lead. Furthermore, continued advances in AI technology are improving diagnostic capacities in this market, accelerating its growth.

Artificial Intelligence (AI) In Diagnostics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Artificial Intelligence in Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to dominate artificial intelligence in diagnostics market during the forecast period due to several factors, including the region's superior healthcare infrastructure, major investment in R&D, and the presence of leading AI technology businesses. Furthermore, the rising frequency of chronic diseases and a lack of healthcare experts, notably radiologists, are driving the demand for AI solutions that improve diagnostic accuracy and efficiency in clinical settings.

Key Players

  • The "Artificial Intelligence (AI) In Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Siemens Healthineers, Zebra Medical Vision, Riverain Technologies, Vuno, Inc., Aidoc, Neural Analytics, Imagen Technologies, Digital Diagnostics, Inc., GE Healthcare, AliveCor, Enlitic, and InformAI.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Artificial Intelligence (AI) In Diagnostics Market Recent Developments
  • In May 2023, Metropolis Healthcare Limited announced the launch of a cutting-edge testing platform that uses Component Resolved Diagnostics (CRD) to identify various allergies in India. The 4th generation of allergy testing technology now includes artificial intelligence to assist clinicians in making informed judgments. It provides valuable insights on optimizing treatment for allergic diseases.
  • In March 2023, Qritive launched QAi Prostate, an AI-powered prostate cancer diagnostic tool for pathologists. The tool uses cutting-edge machine learning algorithms to accurately identify prostatic adenocarcinoma regions and classify malignant and benign tumors in biopsy tissue samples.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Artificial Intelligence (AI) In Diagnostics Market, By COMPONENT

  • Hardware
  • Software

5. Artificial Intelligence (AI) In Diagnostics Market, By DIAGNOSIS

  • Oncology
  • Radiology
  • Pathology
  • Cardiology
  • Chest and Lung
  • Neurology
  • Others

6. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

7. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

8. Competitive Landscape

  • Key Players
  • Market Share Analysis

9. Company Profiles

  • Siemens Healthineers
  • Zebra Medical Vision
  • Riverain Technologies
  • Vuno, Inc.
  • Aidoc
  • Neural Analytics
  • Imagen Technologies
  • Digital Diagnostics, Inc.
  • GE Healthcare
  • AliveCor
  • Enlitic
  • InformAI

10. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

11. Appendix

  • List of Abbreviations
  • Sources and References
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦